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The limitations of the presently used troponin assays when
obtained early after presentation in patients with chest pain
are well documented. Their sensitivity and speciﬁcity for
acute myocardial infarction (MI) are 77% and 93% for
troponin I and 80% and 91% for troponin T (1), respec-
tively. A second draw several hours later increases the
sensitivity, but the cost effectiveness of this approach is poor
(1). The use of these troponin assays in hospitalized patients
is fraught with peril as there are innumerable causes of
“troponinitis” that are unrelated to an acute coronary syn-
drome. This scenario has made the inpatient consultation for
troponin elevation into the bane of the consulting cardiol-
ogist. The myriad causes of troponin elevation have been
recently reviewed in a consensus document (2) and include
myocarditis, Takotsubo cardiomyopathy, heart failure, hy-
pertensive urgency, trauma, cardioversion or cardiopulmo-
nary resuscitation, atrial ﬁbrillation with rapid ventricular
response, chronic kidney disease, sepsis, and pulmonary
embolism.See page 1441More recently, the potential clinical utility of the new
highly sensitive cardiac troponin T assays (hs-cTnT) have
been touted (3,4). These new assays can detect cTnT con-
centrations 10-fold lower than current assays (5). They in-
crease the sensitivity for acute MI but at the price of a
reduction in speciﬁcity that could lead to a plague of “tro-
poninitis” and confusion to the clinical cardiology com-
munity regarding interpretation of these values. Serial*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
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ischemia/infarction are most useful in this setting to deter-
mine whether the ﬁrst measure was an indication of myo-
cardial ischemia or not. A useful algorithm has been recently
proposed for interpretation of these levels and distinguishing
ischemic mechanism from nonishcemic myocardial injury
or other underlying structural heart disease (4).
These ultrasensitive assays have been carefully tested in
the emergency department (ED) setting. In a multicenter
study of 718 patients, the area under the receiver-operating
characteristic curve for the correct diagnosis of acute MI
(17% of the patients) ranged between 0.95 and 0.96 com-
pared with 0.90 for standard troponin assays (6). Similarly,
in a multicenter study of a sensitive troponin I assay in 1,818
consecutive patients, sensitivity and speciﬁcity for acute MI
were 91% and 90%, respectively (7). In a single center study
of 377 patients with chest pain and low-to-intermediate
likelihood of acute coronary syndrome (ACS) (9.8% ulti-
mately positive), the hs-cTnT assay detected 27% more
ACS cases than did standard troponin assays and a level
>99th percentile predicted ACS with a hazard ratio of 9.0
(8). However, in this study, because of the low prevalence
of true positives, the positive predictive value was only 38%.
This ﬁnding points out for the need of assessing the pre-test
likelihood of disease in the patients in the ED because
a single level of hs-cTnT, although sensitive, may be
misleading in the wrong clinical scenario.
Elevations in these novel biomarkers have been shown to
have prognostic implications in normal patient populations
entered into large screening databases. In the DHS study
(Dallas Heart Study) of 3,593 normal subjects 30 to 65
years of age, hs-cTnT was elevated in 25% of individuals,
whereas standard troponin T was only elevated in 0.7% (9).
When the patients were stratiﬁed by baseline hs-cTnT level
and followed for 6.4 years, those with elevated hs-cTnT
over 14 pg/ml (99th percentile) had a signiﬁcantly higher
all-cause mortality (up to 28.4%) compared with the rest of
the study population. Similarly, CHS study (Cardiovascular
Health Study) of 4,221 adults over 65 years of age without
prior heart failure showed that those with the a cTnT
>12.94 pg/ml had a hazard ratio of 2.5 for heart failure
and 2.9 for cardiovascular death compared with those with
undetectable cTnT (10). A recent study from the same
database demonstrated that a baseline hs-cTnT level >12.1
pg/ml was associated with a 1.89 risk of sudden cardiac
death when fully adjusted for other risk factors (11). In
the ARIC (Atherosclerosis Risk in Communities) study of
9,698 individuals 54 to 74 years of age, those with levels
>14 pg/ml (7.4% of the population) had a hazard ratio of
2.3 for coronary heart disease and 7.6 for fatal coronary
heart disease (12). Clearly, hs-cTnT is a marker of adverse
cardiovascular outcome in large populations of normal older
individuals.
The paper in this issue of the Journal by Gore et al. (13)
presents convincing data in regard to the ﬂaws in the
presently used 99th percentile for the high-sensitivity
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1450troponin T assay that sits at 14 pg/ml. With data from
12,618 patients culled from the DHS, ARIC, and CHS
study cohorts discussed previously, they demonstrate that
the 99th percentile in these studies would be 18, 22, and 36
pg/ml in the respective studies and slightly lower when
patients with left ventricular hypertrophy or dysfunction,
and high N-terminal brain natriuretic peptide levels were
excluded. The authors (13) demonstrate that with the
presently used level of 14, up to 10% of men over age 65
years would meet the criteria for acute MI if blood was
drawn at baseline. This paper clearly delineates the need for
age, sex, and racial cutoffs for hs-cTnT in the same way
that there is such stratiﬁcation for coronary calcium scores
developed from the MESA (Multi-Ethnic Study of Ath-
erosclerosis) study (14). In fact, there is a calculator using
the MESA study database to calculate arterial age based on
age, sex, and race (15). A similar calculator could be de-
veloped using the databases studied in the paper by Gore
et al. (13) for hs-cTnT that would be useful for determining
the meaning of any isolated value based on the patient’s
demographics.
The major downside of the analysis in the current paper
by Gore et al. (13) is that it is retrospective in nature
and thus not ideal to truly test these cutoffs for hs-cTnT
prospectively. A prospective study in a large multiethnic
population of diverse ages would be most useful. It might
also be helpful, especially for understanding racial variation,
to test blood from MESA study participants if it is avail-
able. As it stands now, reasonable numbers of African
Americans were tested in the DHS study, but few from
other racial and ethnic groups were represented in any of
the cohorts tested. We, as a cardiology community, have
work to do if we wish to avoid the imminent plague
of troponinitis that will be upon us if we are unable to
interpret the hs-cTnT assays that will undoubtedly be
coming to an ED and intensive care unit near us very soon.
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